Protein arginine methyltransferase 5 inhibition often leads to a decrease in cell growth and survival in cancer cell lines. GSK3326595 is a first-generation protein arginine methyltransferase 5 inhibitor.
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
Annals of Oncology | | M.M. Gounder, P. Martin-Romano, A. Italiano, L.L. Siu, P.A. Cassier, G.S. Falchook, I.S. Lossos, D.W. Rasco, J.F. Hilton, M.A. McKean, F.L. Opdam, J. Strauss, M. De Jonge, J.S.P. Vermaat, T. Crossman, M. Zajac, A. Tarkar, F. Gonzalez Carreras, B.E. Kremer, O. Barbash, S. Segal, R. Parasrampuria, S. Postel-Vinay
Topics: immunotherapy, clinical-trials, research